DDInter1293 DDInter1016
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). A Phase I clinical trial in 2006 showed that this drug was relatively safe and offered significant therapeutic benefits in cases of CML which were found to be resistant to treatment with imatinib (Gleevec), another tyrosine kinase inhibitor used as a first-line treatment for CML.
Lactitol, also known as 4-β-D-galactopyranosyl-D-glucitol, is a sugar alcohol synthesized from [lactose]. It is used in food manufacturing as a nutritive sweetener and is approximately 35% as sweet as table sugar (i.e. [sucrose]). Clinically, lactitol has been investigated for use as an osmotic laxative and, along with other non-absorbable disaccharides such as [lactulose], in the treatment of hepatic encephalopathy in patients with cirrhosis.[A190915,A190918] Pizensy, an oral lactitol powder for solution, was approved by the FDA for use in chronic idiopathic constipation in February 2020.
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Nilotinib {u} (Compound) treats {v} (Disease) hematologic cancer
Nilotinib {u} (Compound) binds {v} (Gene) CA7
Nilotinib {u} (Compound) upregulates {v} (Gene) HERPUD1
Nilotinib {u} (Compound) is included by {v} (Pharmacologic Class) Protein Kinase Inhibitors
Nilotinib {u} (Compound) downregulates {v} (Gene) BNIP3
Nilotinib {u} (Compound) causes {v} (Side Effect) Lymphopenia
Nilotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Nilotinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Sulfamethoxazole
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Methysergide
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Nilotinib (Compound) treats hematologic cancer (Disease)
Nilotinib (Compound) binds CA7 (Gene)
Nilotinib (Compound) upregulates HERPUD1 (Gene)
Nilotinib (Compound) is included by Protein Kinase Inhibitors (Pharmacologic Class)
Nilotinib (Compound) downregulates BNIP3 (Gene)
Nilotinib (Compound) causes Lymphopenia (Side Effect)
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Nilotinib may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole
Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Methysergide